Chimeric Polypeptides Combining Natriuretic and Angiotensin Segments
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular and renal conditions using natriuretic polypeptides are limited in their ability to effectively stimulate cGMP production and provide diuretic and natriuretic activities, as well as regulate renin and aldosterone production.
Innovation Solution
Designing chimeric polypeptides that combine amino acid segments of natriuretic peptides with angiotensin polypeptides, specifically attaching Ang-(1-7) to the C-terminus of the ring structure of CNP, to stimulate cGMP production and exhibit diuretic, natriuretic, and cardiovascular protective effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chimeric polypeptides combining natriuretic peptide and angiotensin polypeptide segments are designed, then cGMP production and diuretic/natriuretic activities are enhanced, but polypeptide structure complexity increases
Solution Approach 1:
The patent combines functional segments of natriuretic peptides (ANP, BNP, or CNP) with angiotensin polypeptide segments to create chimeric molecules that integrate multiple biological activities. The chimeric polypeptide comprises an N-terminal segment (1-17 amino acids) from natriuretic peptide, a central ring structure (7-13 amino acids) from natriuretic peptide, and a C-terminal segment (6-11 amino acids) from angiotensin polypeptide, thereby merging the natriuretic/cGMP-activating function with the angiotensin regulatory function into a single therapeutic agent.
Solution Approach 2:
The invention creates composite polypeptide structures by fusing amino acid sequences from different peptide families. The chimeric polypeptide integrates the disulfide-rich ring structure characteristic of natriuretic peptides with the specific C-terminal sequence of angiotensin polypeptides, forming a hybrid molecule that exhibits properties of both parent peptides including cGMP activation, diuretic effect, and renin/aldosterone regulation.
2Reliability
If chimeric polypeptides are designed to stimulate cGMP production and provide diuretic/natriuretic activities, then therapeutic effectiveness improves, but manufacturing and characterization difficulty increases
Solution Approach 1:
The chimeric polypeptide is designed with distinct functional segments that can be independently characterized: an N-terminal segment (1-17 amino acids) containing the signal peptide and part of the hormone chain, a central ring structure (7-13 amino acids) formed by disulfide bonds between cysteine residues, and a C-terminal segment (6-11 amino acids) from angiotensin polypeptide. This segmentation allows for systematic production and quality control of each functional domain.
Solution Approach 2:
The invention optimizes specific parameters of the chimeric polypeptide including the length of the N-terminal segment (1-17 amino acids), the ring structure composition (7-13 amino acids with specific disulfide bridges), and the C-terminal angiotensin segment (6-11 amino acids). These parameter optimizations balance therapeutic effectiveness with manufacturability by maintaining stable secondary structures while enabling standardized production protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric polypeptides demonstrate enhanced cGMP-activating properties, leading to increased glomerular filtration rate, reduced renin and aldosterone production, and improved cardiovascular and renal function, offering potential therapeutic benefits for conditions like cardiac remodeling and ischemia-reperfusion injury.
Implementation Method 1
Natriuretic polypeptides function via guanylyl cyclase receptors (i.e., NPR-A for ANP, BNP, and URO; and NPR-B for CNP) and the second messenger cyclic 3′5′ guanosine monophosphate (cGMP)
Data Source
AI summary
This document provides methods and materials related to natriuretic polypeptides and the use of natriuretic polypeptides to treat cardiovascular and/or renal conditions. For example, chimeric polypeptides having at least one amino acid segment (e.g., N-terminus tail, ring structure, C-terminus tail, or a combination thereof) of a natriuretic peptide (e.g., ANP, BNP, CNP, URO, or DNP) and an amino acid segment of an angiotensin polypeptide (e.g., Ang-(1-7)) are provided.